The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s demonstrating significant potential in clinical trials for addressing obesity. Unlike some available weight loss solutions, retatrutide appears to offer a greater substantial loss in body weight and enhance metabolic markers, pa